Axonics was founded in 2013 and had its initial public offering in fall 2018. In September 2019, the U.S. Food and Drug Administration approved the company's SNM system to treat fecal incontinence.

The suit argued that Axonics’ sacral neuromodulation systems, known as r-SNM, infringed US patents No. 8036756, No. 8626314, and No. 9463324, all of which pertain to the charging, temperature ...

Axonics Modulation Technologies is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for AXNX's full-year earnings has moved 20% higher.

Axonics Modulation Technologies is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for AXNX's full-year earnings has moved 15.1% higher.

"La profunda experiencia de Rinda en tecnología médica, y específicamente con la terapia de neuromodulación sacra (SNM) de Axonics para tratar la vejiga hiperactiva, será invaluable para ...

Axonics (NASDAQ:AXNX) quickly rose 1% after Boston Scientific (BSX) said it will no longer offer Coaptite as of Nov. 1. Investors believe the announcement may mean that Boston Scientific (BSX ...

Axonics (AXNX) is a high-growth medical device company with significant revenue growth opportunities. It has strong growth drivers in place which will support long-term revenue growth.

Device maker Axonics Inc. says its newest system designed to treat incontinence has demonstrated that the battery in the product can last more than two decades inside a body. The University of Alberta ...

Axonics filed two inter partes review (IPR) petitions to challenge various claims of the U.S. Patent Nos. 8,626,314 and 8,036,756 (“the Medtronic Patents”) for obviousness under 35 U.S.C ...

About Axonics Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the ...

Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.